Plain-English translation of NCT06440707 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called cathodal transcranial direct current stimulation (C-tDCS), which involves applying a weak electrical current through small electrodes on the scalp. Researchers believe this gentle electrical stimulation may protect brain cells that aren't getting enough oxygen and blood during a stroke, and may help increase blood flow to the affected area. The study will test different doses of this treatment to find the safest and most effective level.
Stroke happens when a blood clot blocks blood flow to the brain, and many patients cannot have the procedures that remove these clots. This medication aims to provide an additional treatment option that could help protect brain tissue and prevent permanent damage while the body works to restore blood flow naturally.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive either active electrical stimulation or a sham treatment (where the electrodes are placed but no current is delivered). Participants in the active group will wear a cap with five small electrodes for 20 to 60 minutes, with the exact duration and strength depending on which dose tier they're assigned to. You will also have brain imaging scans performed as part of the study, and you will need to return for a follow-up visit at 3 months.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States